Brinker Capital Investments’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.9M | Buy |
89,022
+8,759
| +11% | +$1.65M | 0.13% | 134 |
|
|
2026
Q1 | $15.8M | Buy |
80,263
+68
| +0.1% | +$13.1K | 0.13% | 131 |
|
|
2025
Q4 | $14.7M | Sell |
80,195
-506
| -0.6% | -$88.7K | 0.11% | 168 |
|
|
2025
Q3 | $12.4M | Buy |
80,701
+9,942
| +14% | +$1.5M | 0.1% | 179 |
|
|
2025
Q2 | $9.89M | Sell |
70,759
-3,990
| -5% | -$559K | 0.08% | 228 |
|
|
2025
Q1 | $11M | Buy |
74,749
+164
| +0.2% | +$23.7K | 0.11% | 175 |
|
|
2024
Q4 | $9.77M | Sell |
74,585
-8,385
| -10% | -$1.17M | 0.1% | 201 |
|
|
2024
Q3 | $12.9M | Sell |
82,970
-2,664
| -3% | -$430K | 0.13% | 158 |
|
|
2024
Q2 | $13.4M | Buy |
85,634
+12,663
| +17% | +$1.91M | 0.14% | 142 |
|
|
2024
Q1 | $9.89M | Buy |
72,971
+2,615
| +4% | +$346K | 0.11% | 200 |
|
|
2023
Q4 | $9.74M | Buy |
70,356
+6,802
| +11% | +$884K | 0.11% | 181 |
|
|
2023
Q3 | $8.61M | Buy |
63,554
+15,209
| +31% | +$2.08M | 0.1% | 192 |
|
|
2023
Q2 | $6.92M | Sell |
48,345
-10,858
| -18% | -$1.6M | 0.07% | 256 |
|
|
2023
Q1 | $8.22M | Buy |
59,203
+2,766
| +5% | +$372K | 0.1% | 185 |
|
|
2022
Q4 | $7.65M | Sell |
56,437
-804
| -1% | -$101K | 0.15% | 140 |
|
|
2022
Q3 | $6.28M | Buy |
57,241
+2,321
| +4% | +$294K | 0.13% | 157 |
|
|
2022
Q2 | $7.26M | Buy |
54,920
+5,493
| +11% | +$721K | 0.14% | 154 |
|
|
2022
Q1 | $6.56M | Buy |
49,427
+10,513
| +27% | +$1.26M | 0.1% | 195 |
|
|
2021
Q4 | $4.53M | Buy |
38,914
+1,600
| +4% | +$188K | 0.07% | 299 |
|
|
2021
Q3 | $4.47M | Hold |
37,314
| – | – | 0.07% | 289 |
|
|
2021
Q2 | $4.47M | Buy |
37,314
+36
| +0.1% | +$3.95K | 0.06% | 333 |
|
|
2021
Q1 | $3.71M | Sell |
37,278
-17,858
| -32% | -$1.8M | 0.06% | 325 |
|
|
2020
Q4 | $5.51M | Buy |
55,136
+28,843
| +110% | +$3.06M | 0.09% | 276 |
|
|
2020
Q3 | $2.88M | Buy |
+26,293
| New | +$2.92M | 0.05% | 360 |
|
|
2020
Q1 | – | Sell |
-188
| Closed | -$19K | – | 342 |
|
|
2019
Q4 | $19K | Hold |
188
| – | – | ﹤0.01% | 514 |
|
|
2019
Q3 | $17K | Hold |
188
| – | – | ﹤0.01% | 525 |
|
|
2019
Q2 | $16K | Buy |
+188
| New | +$14.7K | ﹤0.01% | 723 |
|
|
2016
Q4 | – | Sell |
-63
| Closed | -$4K | – | 489 |
|
|
2016
Q3 | $4K | Buy |
+63
| New | +$4.12K | ﹤0.01% | 422 |
|
Other funds holding AZN
EP
IA
Brinker Capital Investments's AZN Position: Q2 2026 in Review
Brinker Capital Investments increased its AstraZeneca (AZN) stake by 11% in Q2 2026, buying an estimated $1.65M and bringing the position to 89,022 shares worth $16.9M. The position accounts for 0.13% of the portfolio, ranked #134.
Brinker Capital Investments first reported a position in AZN in Q3 2016 and has held it in 28 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Brinker Capital Investments held 89,022 shares of AstraZeneca worth $16.9M as of Q2 2026.
- Brinker Capital Investments bought 8,759 AstraZeneca shares in Q2 2026, an estimated $1.65M.
- AstraZeneca made up 0.13% of Brinker Capital Investments's portfolio in Q2 2026, its #134 holding.
- Brinker Capital Investments first reported a position in AstraZeneca in Q3 2016 and has held it in 28 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.